Design Therapeutics, Inc.DSGNEarnings & Financial Report
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
DSGN Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-19.3M
Net Profit
$-17.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.30
Design Therapeutics, Inc. Q3 2025 Financial Summary
Design Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-17.0M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-17.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Assets | $237.5M | $222.9M | $211.8M |
| Liabilities | $9.6M | $9.8M | $12.1M |
| Equity | $227.9M | $213.0M | $199.7M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|
| Operating CF | $-16.8M | $-14.4M | $-11.2M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M